2型糖尿病并心力衰竭患者应用磷酸西格列汀的疗效和安全性的临床观察被引量：6

导出

摘要目的观察应用磷酸西格列汀治疗2型糖尿病并心力衰竭患者的有效性和安全性.方法 36例使用胰岛素控制血糖的2型糖尿病并心力衰竭患者按随机数字表法分为两组,实验组在原有治疗基础上加用磷酸西格列汀100 mg,1次/d,对照组继续使用胰岛素,两组均根据血糖情况调整胰岛素用量,为期24周.结果治疗24周后,实验组空腹血糖（FPG）、餐后2h血糖（2 h PG）、糖化血红蛋白（HbAlc）及体质量指数（BMI）较对照组明显降低（P＜0.01）,TC、TG、LDL-C与对照组比较差异无统计学意义（P＞0.05）,实验组胰岛素用量减少至（26.9 ±8.1）U/d,对照组胰岛素用量增加至（35.3±12.4） U/d,两组比较差异有统计学意义（P＜0.05）,实验组心脏超声检查左室射血分数[（LVEF：（41.8±7.7）％]较对照组提高[（38.3±7.9）％],但差异无统计学意义（P＞0.05）,与治疗前（36.1±6.7）％相比,差异有统计学意义（P＜0.05）;实验组3例发生低血糖事件,对照组4例发生低血糖事件,两组比较差异无统计学意义（P＞0.05）,实验组2例发生轻度消化道反应,均在1周左右逐渐缓解,未发生其他不良反应.结论应用磷酸西格列汀可以安全有效地改善2型糖尿病并心力衰竭患者的血糖控制情况,同时还可以降低体质量,改善心功能.

作者李进王俊宏樊楠楠

机构地区平顶山市第一人民医院内分泌代谢科平顶山市第一人民医院心内科

出处《中国医师杂志》 CAS 2014年第12期1694-1696,共3页 Journal of Chinese Physician

关键词糖尿病 2型/并发症心力衰竭/并发症二肽基肽酶Ⅳ抑制剂/治疗应用

分类号 R587.1 [医药卫生—内分泌] R541.6 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献10

1纪立农.肠促胰素在2型糖尿病治疗中的作用[J].中华内分泌代谢杂志,2010,26(8):737-740. 被引量：11
2Inzucchi SE, Masoudi FA, McGuire DK. Metformin therapy in pa- tients with type diabetes complicated by heart failure [ J ]. Am Heart J,2007,154(6) :e45.
3Home PD, Pocock SJ, Beck-Nielsen H, et al . Rosiglitazone evalu- ated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD) : a multicentre, randomised, open- label trial[J]. Lancet,2009,373 (9681) :2125-2135.
4VilsboU T, Rosenstock J, YkioJarvinen H, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes [ J ]. Diabetes Obesity Metabolism, 2010, 12 ( 2 ) : 167- 177.
5王晶,宋民喜,徐琳,王钰.胰岛素联合西格列汀治疗2型糖尿病患者临床观察[J].中国医师杂志,2014,16(3):341-343. 被引量：4
6Hong ES, Khang AR, Yoon JW, et al. Comparison between sitaglip- tin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes : CSI study [ J ]. Diabetes ObesMetab ,2012,14 (9) :795-802.
7杨文英.DPP-4抑制剂的心血管保护作用[J].中华内分泌代谢杂志,2014,30(1):79-82. 被引量：10
8Gomez N, Touihri K, Matheeussen V, et al. Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure[J]. Eur J Heart Fail,2012 ,14(1) :14-21.
9dos Santos L, Salles TA, Arruda-Junior DF, et al. Circulating dipeptidyl peptidase IV activity correlates with cardiac dysfunction in human and experimental heart failure [ J ]. Circ Heart Fail, 2013,6(5) :1029-1038.
10Schean AJ. Cardiovascular effects of dipeptidyl peptidase-4 in- hibitors: from risk factors to clinical outcomes [ J ]. Postgrad Med ,2013 , 125 (3) :7-20.

二级参考文献70

1Moore B,Edie ES,Abram JH.On the treatment of diabetes mellitus by acid extract of duodenal mucous membrane.Biochem J,1906,1:28-38.
2Zunz E,La Barre J.Contributions a letude des variations physiologiques de la seretion inteme du pancreas:relations entre les seretions exteme et interne di pancreas.Arch Int Physiol,1929,31:20-44.
3Elrick H,Stimmler L,Hlad CJ,et al.Plasma insulin response to oral and intravenous glucose administration.J ClinEndocrinol Metab,1964,24:1076-1082.
4Ding WG,Gromada J.Protein kinase A-dependent stimulation of exocytosis in mouse pancreatic beta-cells by glucose-dependent insulinotropic polypeptide.Diabetes,1997,46:615-621.
5Bollag RJ,Zhong Q,Ding KH,et al.Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects.Mol Cell Endocrinol,2001,177:35-41.
6Nauck MA,Bartels E,Orskov C,et al.Lack of effect of synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1[7-36 amide] infused at near-physiological concentrations on pentagastrin-stimulated gastric acid secretionin normal human subjects.Digestion,1992,52:214-221.
7Salehi M,Aulinger BA,D'Alessio DA.Targeting β-cell mass in type 2 diabetes:promise and limitations of new drugs based on incretins.Endocr Rev,2008,29:367-379.
8Holz GG,Kuhtreiber WM,Habener JF.Pancreatic β-cells are rendered glucose-competent by the insulinotropic hormone glucagonlike peptide-1 (7-37).Nature,1993,361:362-365.
9Gromada J,Bokvist K,Ding WG,et al.Glucagon-like peptide 1(7-36) amide stimulates exocytosis in human pancreatic β-cells by both proximal and distal regulatory steps in stimulus-secretion coupling.Diabetes,1998,47:57-65.
10Knop FK.Reduced incretin effect in type 2 diabetes:cause or consequence of the diabetic state? Diabetes,2007,56:1951-1959.